Latest news with #JackLee
Yahoo
15-05-2025
- Business
- Yahoo
Bullard ISD delays opening of new middle school till 2026
BULLARD, Texas (KETK) – Bullard ISD has announced that the opening of their new 179,000 square-foot middle school campus has been delayed. The new campus was originally scheduled to open by August 2025, but due to delays, the district leadership and construction teams announced on Thursday that the new building is now expected to open in January 2026. Students and staff are expected to move into the new campus at the start of the spring semester of the 2025-2026 school year. Texas bill allows food truck owners to simplify permits in each county The new campus will house 1200 students, including sixth, seventh and eighth graders, and will all be in one building together for the first time. The new campus will also include state-of-the-art classrooms and technology. Tyler ISD celebrates 2025 Project SEARCH graduates According to Bullard ISD, the physical construction of the building is still on pace to be finished on schedule, but infrastructure needs are causing the campus opening to be delayed. Bullard ISD Superintendent Dr. Jack Lee spoke about the delay and challenges they have had to overcome in order to create the new campus. 'We are incredibly proud of the design and construction of our new middle school campus,' Lee said. 'Unfortunately, no construction project of this size can be completed without challenges arising. Although we have been working on building infrastructure since the design phase of the new campus, we continue to face challenges created by substantial weather delays, utility connections, access to public and private easements, and the road construction at FM2493 and US69. Dr. Jack Lee Dr. Lee said that the district is in contact with everyone involved in the new middle school and is grateful for everyone's support and patience. 'Bullard ISD remains in close communication with all involved parties, and the district looks forward to celebrating the opening of the new Bullard Middle School as soon as it is ready to safely welcome students and staff,' Dr. Lee said. 'We are grateful for the patience, support, and understanding of our parents, staff, and students throughout this process.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Korea Herald
22-04-2025
- Health
- Korea Herald
UK Clinical Study Finds Sky Labs' Smart Ring 'CART-I' More Sensitive Than Apple Watch for AFib Detection
SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- Sky Labs, a health-tech startup based in South Korea, announced that its ring-shaped smart medical device, CART-I (Cardio Tracker), demonstrated higher sensitivity than the Apple Watch in detecting atrial fibrillation (AFib) in a recent clinical study. The study's findings were published in Heart Rhythm O 2, a peer-reviewed international journal. "This study offers strong external validation of CART-I's performance in detecting atrial fibrillation," said Jack Lee, CEO of Sky Labs. "Together with CART BP, which focuses on hypertension management, these results demonstrate CART-I's potential to support broader cardiovascular monitoring in the future. We will continue to develop medical devices that deliver both accuracy and convenience for patients." The comparative study, conducted across three hospitals in the UK (Oxford University Hospital, University Hospital Southampton, and Queen Elizabeth Hospital), involved approximately 500 patients and evaluated CART-I and Apple Watch under the same clinical protocol. Researchers assessed the sensitivity and specificity of each device's automatic AFib detection algorithms using single-lead electrocardiograms (SL-ECG) data, which was subsequently interpreted by physicians. Results showed that Sky Labs' CART-I achieved 84.6% sensitivity, while Apple Watch recorded 69.1% under the same protocol. Both devices also demonstrated high performance in physician interpretation of SL-ECGs: the Apple Watch scored 95.4% sensitivity, and CART-I recorded 94.3%. Unlike prior studies that focused solely on atrial fibrillation, this research is especially meaningful for its inclusion of a broad range of arrhythmias such as atrial flutter and atrial tachycardia. Researchers noted, however, that wearable devices alone are not yet sufficient for diagnosing specific arrhythmias such as atrial flutter or atrial tachycardia. Physician interpretation remains essential, and automated algorithms should be considered as supportive tools rather than standalone diagnostic solutions. Separately, Sky Labs' cuffless ring-type blood pressure monitor, CART BP, was recently awarded the 2024 Prime Minister's Prize at the IR52 Jang Young-sil Awards, one of Korea's most prestigious recognitions for technological innovation. CART BP was selected for fulfilling all four key evaluation criteria: economic value, technological importance, originality, and technological independence. CART BP is an innovative medical device that transforms traditional blood pressure monitoring by replacing cuff-based, intermittent arm measurements with comfortable, finger-based monitoring over a 24-hour period. The device received regulatory approval from the Korean Ministry of Food and Drug Safety in 2023 and was approved for national health insurance reimbursement in 2024. As of April 2025, CART BP pro is in use at more than 1,300 hospitals and clinics across South Korea, supporting daily blood pressure monitoring and management. About Sky Labs Founded in September 2015, Sky Labs is a leading healthcare startup that has developed CART (Cardio Tracker), a ring-shaped medical device designed for disease monitoring using heart signals collected through optical sensors. Following this, the company developed CART BP, a cuffless, ring-shaped device that enables 24-hour blood pressure monitoring, providing valuable treatment information and making a groundbreaking contribution to improving the quality of life for hypertension patients. Sky Labs has signed an exclusive domestic distribution agreement for CART BP pro with South Korea's Daewoong Pharmaceutical and is preparing for nationwide sales to hospitals, clinics, and general consumers.
